

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>Gergel Ivan P.</u> _____ (Last) (First) (Middle) <u>C/O ENDO INTERNATIONAL PLC</u> <u>25-28 NORTH WALL QUAY</u> _____ (Street) <u>DUBLIN L2 1</u> _____ (City) (State) (Zip)			2. Issuer Name and Ticker or Trading Symbol <u>Endo International plc [ENDP]</u>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>EVP, R&D and CSO</u>		
			3. Date of Earliest Transaction (Month/Day/Year) <u>03/10/2014</u>					
			4. If Amendment, Date of Original Filed (Month/Day/Year)					
			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person					

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Ordinary Shares	03/10/2014		M		15,742	A	\$20.61	43,391	D	
Ordinary Shares	03/10/2014		S		15,742	D	\$72.47 ⁽¹⁾	27,649	D	
Ordinary Shares	03/10/2014		M		31,162	A	\$33.98	58,811	D	
Ordinary Shares	03/10/2014		S		31,162	D	\$72.47 ⁽¹⁾	27,649	D	
Ordinary Shares	03/10/2014		M		22,126	A	\$34.7	49,775	D	
Ordinary Shares	03/10/2014		S		22,126	D	\$72.47 ⁽¹⁾	27,649	D	
Ordinary Shares	03/10/2014		M		6,607	A	\$30.8	34,256	D	
Ordinary Shares	03/10/2014		S		6,607	D	\$72.47 ⁽¹⁾	27,649	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
2004 Stock Incentive Plan Stock Options (NQ)	\$20.61	03/10/2014		M			15,742	(2)	02/19/2020	Ordinary Shares	15,742	\$0.00 ⁽³⁾	0	D	
2010 Stock Incentive Plan Stock Options (NQ)	\$33.98	03/10/2014		M			31,162	(4)	02/23/2021	Ordinary Shares	31,162	\$0.00 ⁽³⁾	10,387	D	
2010 Stock Incentive Plan Stock Options (NQ)	\$34.7	03/10/2014		M			22,126	(5)	02/22/2022	Ordinary Shares	22,126	\$0.00 ⁽³⁾	22,124	D	
2010 Stock Incentive Plan Stock Options (NQ)	\$30.8	03/10/2014		M			6,607	(6)	02/27/2023	Ordinary Shares	6,607	\$0.00 ⁽³⁾	19,820	D	

Explanation of Responses:

- This represents the price at which Dr. Gergel's ordinary shares were sold on March 10, 2014.
- Dr. Gergel's stock options that were granted under the 2004 Stock Incentive Plan on February 19, 2010, were generally exercisable 25% per year on each of February 19, 2011, February 19, 2012, February 19, 2013 and February 19, 2014.

3. These securities were granted to Dr. Gergel in consideration of his services as Executive Vice President, Research & Development & Chief Scientific Officer of Endo Health Solutions Inc.
4. Dr. Gergel's stock options that were granted under the 2010 Stock Incentive Plan on February 23, 2011, were or are generally exercisable 25% per year on each of February 23, 2012, February 23, 2013, February 23, 2014 and February 23, 2015.
5. Dr. Gergel's stock options that were granted under the 2010 Stock Incentive Plan on February 22, 2012, were or are generally exercisable 25% per year on each of February 22, 2013, February 22, 2014, February 22, 2015 and February 22, 2016.
6. Dr. Gergel's stock options that were granted under the 2010 Stock Incentive Plan on February 27, 2013, were or are generally exercisable 25% per year on each of February 27, 2014, February 27, 2015, February 27, 2016 and February 27, 2017.

Remarks:

[/s/ Caroline B. Manogue, by
power of attorney](#) [03/11/2014](#)

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

LIMITED POWER OF ATTORNEY FOR
SECTION 16 REPORTING OBLIGATIONS

Know all by these present that the undersigned hereby makes, constitutes and appoints Caroline B. Manogue and Daniel Rudio as the undersigned's true and lawful attorneys-in-fact, with full power and authority as hereinafter described on behalf of and in the name, place and stead of each of the undersigned to:

(1) prepare, execute, acknowledge, deliver and file Forms 3, 4, and 5 (including any amendments thereto) with respect to the securities of Endo Pharmaceuticals Holdings Inc., a Delaware corporation (the "Company"), with the United States Securities and Exchange Commission, any national securities exchanges and the Company, as considered necessary or advisable under Section 16(a) of the Securities Exchange Act of 1934 and the rules and regulations promulgated thereunder, as amended from time to time (the "Exchange Act");

(2) seek or obtain, as the undersigned's representative and on the undersigned's behalf, information on transactions in the Company's securities from any third party, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to the undersigned and approves and ratifies any such release of information; and

(3) perform any and all other acts which in the discretion of such attorney-in-fact are necessary or desirable for and on behalf of the undersigned in connection with the foregoing.

The undersigned acknowledges that:

(1) this Power of Attorney authorizes, but does not require, such attorney-in-fact to act in their discretion on information provided to such attorney-in-fact without independent verification of such information;

(2) any documents prepared and/or executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney will be in such form and will contain such information and disclosure as such attorney-in-fact, in his or her discretion, deems necessary or desirable;

(3) neither the Company nor such attorney-in-fact assumes (i) any liability for the undersigned's responsibility to comply with the requirement of the Exchange Act, (ii) any liability of the undersigned for any failure to comply with such requirements, or (iii) any obligation or liability of the undersigned for profit disgorgement under Section 16(b) of the Exchange Act; and

(4) this Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned's obligations under the Exchange Act, including without limitation the reporting requirements under Section 16 of the Exchange Act.

The undersigned hereby gives and grants the foregoing attorney-in-fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary or appropriate to be done in and about the foregoing matters as fully to all intents and purposes as the undersigned might or could do if present, hereby ratifying all that such attorney-in-fact of, for and on behalf of the undersigned, shall lawfully do or cause to be done by virtue of this Limited Power of Attorney.

This Power of Attorney shall remain in full force and effect with respect to each undersigned until revoked by such undersigned in a signed writing delivered to such attorney-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 29th day of April 2008.

SIGNATURE

TITLE

/S/ IVAN GERGEL Executive Vice President, Research & Development
Ivan Gergel

STATE OF PENNSYLVANIA:
COUNTY OF DELAWARE:

On this 29th day of April 2008, the above-named individual personally appeared before me, and acknowledged that he executed the foregoing instrument for the purposes therein contained.

IN WITNESS WHEREOF, I have hereunto set my hand and official seal.

/S/ SUSAN E. DEAR

Notary Public

Commonwealth of Pennsylvania

Notarial Seal

Susan E. Dear, Notary Public

Concord Twp., Delaware County

My Commission Expires on January 8, 2009